UCSF Center for HIV Information

University of California, San Francisco

1700 Owens Street, Suite 316
San Francisco, CA 94158
United States

Articles: 36

Title Sort ascending Publish date Review date
Use of Dolutegravir in Dialysis
Updates on Mpox: Vaccination Efficacy and Spectrum of Disease in People with HIV
Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy
Updated CDC PrEP Guidelines
Tissue Levels of TAF: Too Low for PrEP?
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women
Switching from TDF/FTC to TAF/FTC
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
Safety of Dolutegravir at Conception: Updated Data
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Rapid ART Start
PrEP: TDF/FTC vs TAF/FTC in MSM
PrEP: Bone Density Improves after Stopping TDF/FTC
New ARV Approval - Fostemsavir
Naltrexone Improves Virologic Suppression
Long-acting Injectable PrEP: Cabotegravir
Long-acting Injectable PrEP Approved: Cabotegravir
Long-Acting Injectable ART: Cabotegravir + Rilpivirine
Immediate ART Initiation Improves Time to Viral Suppression
Ibalizumab Approved for Persons with Multidrug Resistant HIV
HIV Meds Updates: Long-acting Injectable Therapy: Lenacapavir
HIV Meds Updates - TANGO and SALSA Studies: Switch to DTG/3TC from 3-Drug ART
HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine
HIV Meds Update: FDA Approves Lenacapavir, New Long-Acting Injectable ARV
HIV Meds Update: DoxyPEP – Doxycycline for STI Prevention
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA
HIV Meds Update: Anal Dysplasia Treatment Prevents Anal Cancer - The ANCHOR Study
HIV Meds Update - RAPID: Immediate ART Initiation
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects
Dolutegravir + 3TC in Initial Therapy
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study
Bictegravir/TAF/FTC in Women
Bictegravir Approved for Initial ART, in Combination with TAF/FTC